Prognostic importance of thrombospondin-1, VEGF, PDGFR- β in diffuse large B-cell lymphoma

Year 2022, Volume: 5 Issue: 5, 1505 - 1511, 25.09.2022

Adnan Batman , Rafiye Ciftciler , Elif Birtaş Ateşoğlu , Abdullah Hacıhanefioğlu

https://doi.org/10.32322/jhsm.1146953

Abstract

Aim: In this study, we aimed to investigate the relationship between the staining rates of thrombospondin-1, VEGF, and PDGFR-in tissue preparations in patients diagnosed with DLBCL and their clinical features at the time of diagnosis, and response to treatment and prognosis.
Material and Method: A total of 44 patients with a diagnosis of DLBCL and 13 patients diagnosed with control reactive lymphadenopathy were included in this study. After immunohistochemical staining of the pathology preparations of the patient and control groups with VEGF, PDGFR-β and thrombospondin-1 stains, the clinical characteristics of the patients and the relationship between survival analysis and staining rates were statistically analyzed.
Results: When the patients were compared with the control group in terms of VEGF, PDGFR-β, and thrombospondin-1 staining rates, we found that staining with PDGFR-β was lower in patients (p=0.009). Although it was not statistically significant for PDGFR-β, it was observed that 5-year OS and PFS values were low in patients with high levels of expression, on the contrary, 5-year OS was low in patients with high thrombospondin staining rate. A negative correlation was observed between thrombospondin-1 and PDGFR-β (p=0.003, r=-0.440).
Conclusion: As a result, although no relationship was found between VEGF and survival in our study, it was observed that PDGFR-β and thrombospondin-1 were effective in prognosis. A negative correlation was observed between thrombospondin-1 and PDGFR-β.

Keywords

Diffuse large B cell lymphoma, thrombospondin-1, VEGF, PDGFR-β, prognosis

References

• Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med 2021; 384: 842-58.
• Solimando AG, Annese T, Tamma R, et al. New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers (Basel) 2020; 12: 1869.
• Riccardi C, Napolitano E, Platella C, Musumeci D, Melone MAB, Montesarchio D. Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics. Med Res Rev 2021; 41:464-506.
• Ruan J, Luo M, Wang C, et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 2013; 121: 5192-202.
• Kaur S, Bronson SM, Pal-Nath D, Miller TW, Soto-Pantoja DR, Roberts DD. Functions of Thrombospondin-1 in the Tumor Microenvironment. Int J Mol Sci 2021; 22: 4570.
• Wang P, Zeng Z, Lin C, et al. Thrombospondin-1 as a Potential Therapeutic Target: Multiple Roles in Cancers. Curr Pharm Des 2020; 26 :2116-36.
• Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response evaluation criteria in lymphoma . Ann Oncol 2017; 28: 1436-47.
• Al-Ostoot FH, Salah S, Khamees HA, Khanum SA. Tumor angiogenesis: Current challenges and therapeutic opportunities. Cancer Treat Res Commun 2021; 28: 100422.
• Paydas S, Ergin M, Seydaoglu G, Erdogan S, Yavuz S. Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leukemia Res 2009; 33: 1627-35.
• Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000; 96: 3181-7.
• Doussis‐Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin–Reed–Sternberg cells in Hodgkin’s disease. J Pathol 2002; 197: 677-83.
• Menzel L, Höpken UE, Rehm A. Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth. Front Immunol 2020; 11: 591741.
• Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-21.
• Fragoso R, Pereira T, Wu Y, Zhu Z, Cabeçadas J, Dias S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 2006; 107: 1608-16.
• Riihijärvi S, Nurmi H, Holte H, et al. High serum vascular endothelial growth factor level is an adverse prognostic factor for high‐risk diffuse large B‐cell lymphoma patients treated with dose‐dense chemoimmunotherapy. Eur J Haematol 2012; 89: 395-402.
• Salven P, Orpana A, Teerenhovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 2000; 96: 3712-8.
• Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin’s lymphoma. Leukemia lymphoma 2003; 44: 2089-93.
• Tzankov A, Heiss S, Ebner S, et al. Angiogenesis in nodal B cell lymphomas: a high throughput study. J Clin Pathol 2007; 60: 476-82.
• Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 2006; 169: 2054-65.
• Shen J, Vil MD, Prewett M, et al. Development of a fully human anti-PDGFRβ antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 2009; 11: 594-604.
• Sano H, Ueda Y, Takakura N, et al. Blockade of platelet-derived growth factor receptor-β pathway induces apoptosis of vascular endothelial cells and disrupts glomerular capillary formation in neonatal mice. Am J Pathol 2002; 161: 135-43.
• Albo D, Tuszynski G. Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells. J Surg Res 2004; 120: 21-6.
• Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U. Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin’s lymphomas. Leukemia Research 2008; 32: 243-50.